Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Sangamo Therapeutics Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. Each matter is associated with a distinct examiner and a distinct art unit, producing 5 examiner assignments and 5 art-unit assignments. WILSON, MICHAEL C is the busiest examiner, with 1 pending action.
The matching distribution indicates that prosecution is spread across the portfolio rather than concentrated in a shared examination path. Counsel should maintain application-specific response plans and use a central review to prevent inconsistent treatment of related biotechnology claims. The WILSON file identifies one examiner relationship, but the data does not show repeated assignment to that examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (33%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
| SU-TOBON, QIWEN NMN | 1 | 66.7% | +66.7% |
| RYAN, DOUGLAS CHARLES | 1 | 38.2% | +48.4% |
| CHOWDHURY, IQBAL HOSSAIN | 1 | 73.6% | +57.6% |
| WESTON, ALYSSA G | 1 | 59.5% | +49.0% |
| HILL, MYRON G | 1 | 66.1% | +20.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029806 | METHODS OF DETECTING ANTI-AAV ANTIBODIES | HILL, MYRON G | 14d |
| 18707085 | METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE | SU-TOBON, QIWEN NMN | — |
| 18609899 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RARE DISEASES | RYAN, DOUGLAS CHARLES | — |
| 18249418 | GENERATION OF CD4+ EFFECTOR AND REGULATORY T CELLS FROM HUMAN PLURIPOTENT STEM CELLS | WESTON, ALYSSA G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029806 | METHODS OF DETECTING ANTI-AAV ANTIBODIES | HILL, MYRON G | 14d |
| 18895313 | T CELL MODIFYING COMPOUNDS AND USES THEREOF | WILSON, MICHAEL C | — |
| 18707085 | METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE | SU-TOBON, QIWEN NMN | — |
| 18609899 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RARE DISEASES | RYAN, DOUGLAS CHARLES | — |
| 18493366 | ENGINEERED TARGET SPECIFIC NUCLEASES | CHOWDHURY, IQBAL HOSSAIN | — |
| 18249418 | GENERATION OF CD4+ EFFECTOR AND REGULATORY T CELLS FROM HUMAN PLURIPOTENT STEM CELLS | WESTON, ALYSSA G | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1636 | 1 |
| 1635 | 1 |
| 1656 | 1 |
| 1633 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18895313 | T CELL MODIFYING COMPOUNDS AND USES THEREOF | WILSON, MICHAEL C | 1638 | §112DP | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18707085 | METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE | SU-TOBON, QIWEN NMN | 1636 | §102§103§112Other | Non-Final OA | — | Pending | May 02, 2024 |
| 18609899 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RARE DISEASES | RYAN, DOUGLAS CHARLES | 1635 | §101§102§103§112DP | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18493366 | ENGINEERED TARGET SPECIFIC NUCLEASES | CHOWDHURY, IQBAL HOSSAIN | 1656 | §112 | Final Rejection | — | Pending | Oct 24, 2023 |
| 18249418 | GENERATION OF CD4+ EFFECTOR AND REGULATORY T CELLS FROM HUMAN PLURIPOTENT STEM CELLS | WESTON, ALYSSA G | 1633 | §102§103§112 | Final Rejection | — | Pending | Apr 18, 2023 |
| 18029806 | METHODS OF DETECTING ANTI-AAV ANTIBODIES | HILL, MYRON G | 1671 | §101§103§112 | Final Rejection | 14d | Pending | Mar 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSangamo Therapeutics Inc. has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Michael C Wilson has the most, with 1 of Sangamo Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
